NEW YORK, November 20, 2025 — Leads & Copy — Axsome Therapeutics, Inc. (NASDAQ: AXSM) will participate in investor conferences in December, the company announced today.
The conferences include:
Piper Sandler 37th Annual Healthcare Conference Fireside Chat: Wednesday, December 3, 2025, at 4:00 p.m. ET in New York, NY.
BofA Securities CNS Therapeutics Virtual Conference 2025 Fireside Chat: Monday, December 8, 2025, at 11:40 a.m. ET.
A live webcast of the presentation at the Piper Sandler conference can be accessed on the “Webcasts & Presentations” page of the “Investors” section of the company’s website. A replay of the webcast will be available for approximately 30 days following the event.
Axsome Therapeutics is a biopharmaceutical company focused on treating central nervous system (CNS) conditions. The company delivers scientific breakthroughs by identifying critical gaps in care and developing differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes.
Axsome’s neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine.
It also includes multiple early and late-stage development programs addressing a range of serious neurological and psychiatric conditions that impact over 150 million people in the United States.
The company’s forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of its SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of its efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05.
The company’s ability to maintain and expand payer coverage; the success, timing and cost of its ongoing clinical trials and anticipated clinical trials for the company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials.
Its ability to fund additional clinical trials to continue the advancement of the company’s product candidates; the timing of and the company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the company’s product candidates, including statements regarding the timing of any NDA submission.
Its ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the company, if at all; the company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements.
Its successful implementation of the company’s research and development programs and collaborations; the success of the company’s license agreements; the acceptance by the market of the company’s products and product candidates, if approved.
The company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the company’s commercial launch of its other product candidates, if approved, and the potential impact on the company’s anticipated cash runway.
Its ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the company’s control.
Investors can contact Ashley Dong, Director of Investor Relations, at (929) 687-1614 or adong@axsome.com. Media inquiries can be directed to Darren Opland, Senior Director, Corporate Communications, at (929) 837-1065 or dopland@axsome.com.
Source: Axsome Therapeutics, Inc.
